| Similar Articles |
|---|
 |
The Motley Fool
January 25, 2007
Brian Gorman |
Covance Stays Solid Despite a run-up in the stock, Covance may be in for yet another solid year.   |
The Motley Fool
April 28, 2006
Brian Gorman |
Speed Bumps at Covance Although some problems have cropped up, this drug-research services company is still a solid performer overall. Investors, take note. |
The Motley Fool
January 27, 2005
Brian Gorman |
Covance's Higher Performance The provider of drug development services' productivity gains and bundled service strategy are driving results. |
The Motley Fool
February 9, 2006
Brian Gorman |
Charles River Bets on Preclinical The company is reportedly seeing more activity from biotech outfits, in addition to existing business from larger pharmaceutical names like Eli Lilly and Pfizer. But a large expansion in preclinical capacity warrants close watching. Investors, take note. |
The Motley Fool
October 21, 2005
Brian Gorman |
Covance Keeps Delivering Investors seemed to fret over the drug-development services company's full-year earnings forecast, but the facts suggest that Covance remains a solid long-term bet. |
The Motley Fool
October 30, 2006
Brian Gorman |
Quality in Covance Some investors are pulling back from the company's stock, but Covance will continue to deliver. |
The Motley Fool
April 25, 2005
Brian Gorman |
Leaning on a Stronger Covance The drug development services company is helping big pharmaceutical firms. While the company's valuation of 24 times 2005 earnings is a bit a rich, Covance should be on investors' radar. |
The Motley Fool
June 15, 2006
Brian Gorman |
Covance Gets Strategic The drug research service company's latest deal could help it cement its leadership in the industry. Investors, take note. |
The Motley Fool
August 9, 2006
Brian Gorman |
Charles River's Uptick The drug research services company looks better than it did last quarter, but it still has its issues. Investors, take note. |
The Motley Fool
July 30, 2009
Robert Steyer |
Covance Advances Covance latest results produce more optimism than did some of its contract research peers. |
The Motley Fool
March 2, 2011
Cindy Johnson |
McDermott International Shares Popped: What You Need to Know Engineering company McDermott International, popped 11% in intraday trading today after news of a higher backlog and new contracts overshadowed a big earnings miss. |
The Motley Fool
October 23, 2009
Robert Steyer |
Taking the Drug Industry's Temperature Covance and Icon hint at broader pharmaceutical R&D trends. |
The Motley Fool
November 7, 2006
Brian Gorman |
Charles River Inches Forward The drug research services company is not out of the woods yet, but some positive signs are emerging. Investors, take note. |
The Motley Fool
October 1, 2008
Brian Orelli |
WuXi and Covance Call It Quits WuXi PharmaTech and Covance broke up yesterday - just three months after announcing they'd form an alliance to perform pre-clinical research for drug developers looking for research and development on the cheap. |
The Motley Fool
April 27, 2010
Brian Orelli |
Big Acquisition, Double-Digit Decline. Charles River Labs buys into China big time. But investors would rather have seen it stay home. |
The Motley Fool
May 4, 2005
Brian Gorman |
Relaxing on the River Charles River Laboratories' full suite of services looks like a winning concept. |
The Motley Fool
May 10, 2006
Brian Gorman |
Charles River Restructures For the near term, restructuring plans should keep this one in limbo. Investors shouldn't expect too much from the company right now. |
The Motley Fool
August 3, 2004
Brian Gorman |
PAREXEL Gets Leaner The research services provider continues to improve operating performance, but that might not affect its stock price. |
The Motley Fool
July 22, 2011 |
Covance Earnings Preview Drug development company Covance beat estimates by $0.02 last quarter, and investors are hoping it can beat them again. |
The Motley Fool
July 22, 2004
Brian Gorman |
Stability for Covance? After a solid quarter, the drug development service company may have found a way to keep revenue consistent. |
The Motley Fool
June 25, 2008
Brian Orelli |
WuXi's Shortsighted Deal WuXi partners with Covance, but is it really a good long-term play? |
The Motley Fool
January 29, 2009 |
Today's 5-Star Movers Today's list of top-moving stocks from the Motley Fool five-star stock list. |
The Motley Fool
July 1, 2004
Brian Gorman |
Charles River's Big Buy Charles River Laboratories is buying Inveresk Research Group in what appears to be a bid to control more of the burgeoning market for preclinical drug development services. |
The Motley Fool
January 28, 2008
Rich Smith |
Northrop Becomes a Guinea Pig Backlog refers to orders that have been booked and are expected to become revenue but haven't yet. Let's take a deeper look at backlog, using Northrop Grumman's fourth-quarter and full-year reports as an example. |
The Motley Fool
August 13, 2009
Brian Orelli |
WuXi: Making Money Both Ways Cost-cutting and revenue growth make pharma outsourcing specialist WuXi a looker for the year. |
The Motley Fool
January 13, 2011
Brian Orelli |
This Trendy Pharma Is Making a Stylish Move Merck signs up a CRO to help with biosimilars. |
The Motley Fool
August 1, 2008
Brian Orelli |
Recession Schmession, This Industry Is On Fire Contract research organizations do pre-clinical research and run clinical trials for drug developers on the cheap. With pharmaceutical companies cutting back on costs, CROs are in the perfect position to benefit. |
The Motley Fool
May 18, 2010
Brian Orelli |
Pfizer Double-Dips Is this the best way to go after multiple indications? The drugs are already approved or have been in the clinic for other indications; thus the double-dipping. |
Chemistry World
November 12, 2014
Phillip Broadwith |
Labcorp to buy Covance and enter contract research Medical diagnostics specialist Labcorp has agreed to buy contract research organization Covance for around $6 billion. |
The Motley Fool
April 24, 2009
Robert Steyer |
Nothing to CRO About The good times have stopped rolling for Contract research organizations, as they warn of unexpected contract cancellations and reduced demand for services. |
Pharmaceutical Executive
December 1, 2012
Torrey et al. |
Transforming Drug Development: A Case Study Eli Lilly's pioneering pact with leading CRO Covance made big news when it happened. Four years later, both parties can point to metrics that suggest the benefit is mutual. |
